



Genocea Biosciences  
Investor Relations Department  
100 Acom Park Drive, 5th Floor  
Cambridge, MA 02140  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: GNCA

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 4.95                       |
| Trade Time:   | 2:23 PM ET<br>Jul 20, 2017 |
| Change:       | -0.02 ↓ (-0.402%)          |
| Day Range     | 4.90 - 5.02                |
| 52-Week Range | 3.28 - 7.29                |
| Volume        | 91,082                     |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases. Genocea's pipeline includes clinical programs addressing genital herpes and pneumococcus and research efforts in... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Jun 26, 2017

[Genocea Added to Russell 3000® and Russell 2000® Indices](#)

May 4, 2017

[Genocea Reports First Quarter 2017 Financial Results and Positive Clinical Developments on Lead Candidate GEN-003 in Genital Herpes](#)

Apr 27, 2017

[Genocea to Host First Quarter 2017 Financial Results Conference Call & Webcast on May 4, 2017 at 9 a.m. ET](#)

Apr 11, 2017

[Genocea Awarded World Vaccine Congress 2017 Industry Excellence Award for Best Therapeutic Vaccine for GEN-003 for Genital Herpes](#)

Mar 29, 2017

[Genocea to Present at the 16th Annual Needham Healthcare Conference](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

Feb 17, 2017

[Annual Report \(10-K\)](#)

Apr 21, 2017

[Proxy Statement \(DEF 14A\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)

Nov 4, 2016

[Quarterly Report \(10-Q\)](#)

Aug 5, 2016

[Quarterly Report \(10-Q\)](#)